Production (Stage)
Calidi Biotherapeutics, Inc.
CLDI
$0.31
-$0.01-3.13%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.70% | 18.94% | 12.36% | 20.18% | 12.20% |
| Total Depreciation and Amortization | 0.25% | 0.77% | 3.17% | 1.07% | 2.75% |
| Total Amortization of Deferred Charges | -- | -55.56% | -43.75% | 0.00% | 105.73% |
| Total Other Non-Cash Items | -5.88% | 77.44% | -54.73% | -39.65% | 3,723.33% |
| Change in Net Operating Assets | -34.89% | -282.65% | 24.32% | -140.53% | -35.84% |
| Cash from Operations | -31.50% | -9.64% | 9.97% | -43.41% | 26.13% |
| Capital Expenditure | -40.00% | 16.67% | -- | 100.00% | 92.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -40.00% | 16.67% | -- | 100.00% | 85.71% |
| Total Debt Issued | -- | -100.00% | -- | -100.00% | -- |
| Total Debt Repaid | -8,673.68% | -5.56% | 99.01% | -7,821.74% | 99.00% |
| Issuance of Common Stock | -26.06% | 264.85% | -32.19% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 40.04% | -129.03% | 14.20% | 1,023.17% | 75.15% |
| Cash from Financing | -38.14% | 116.77% | 16.27% | 72.59% | 201.86% |
| Foreign Exchange rate Adjustments | -- | 148.48% | -153.85% | -176.47% | 189.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -87.39% | 625.16% | 445.60% | 61.91% | 90.17% |